UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

The Uni­ver­si­ty of Penn­syl­va­nia’s pi­o­neer­ing cell ther­a­py physi­cian Carl June shared new da­ta Mon­day that showed the risk of sec­ondary can­cers fol­low­ing CAR-T ther­a­py was very low.

In over 1,500 pa­tients treat­ed at UPenn and Stan­ford Uni­ver­si­ty, on­ly a small per­cent­age had a sec­ond can­cer af­ter treat­ment, June re­port­ed Mon­day morn­ing at a Friends of Can­cer Re­search and Park­er In­sti­tute for Can­cer Im­munother­a­py joint event in Wash­ing­ton.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER